The American Journal of Medicine
Volume 121, Issue 8, Supplement 2 , Pages S27-S33 , August 2008

Improving Therapeutic Outcomes in BPH Through Diagnosis, Treatment and Patient Compliance

  • Joel DeCastro, MD
    • ,
  • Brian Stone, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Brian Stone, MD, Department of Urology, College of Physicians & Surgeons of Columbia University,161 Fort Washington Avenue, New York, New York 10032.

References 

  1. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158:481–487
  2. Sarma AV, Wei JT, Jacobson DJ, et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. Urology. 2003;61:1086–1091
  3. Kaplan SA, Reis RB, Staiman VB, Te AE. Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts?. Br J Urol. 1998;82:804–807
  4. Sidney S, Quesenberry CP, Sadler MC, Guess HA, Lydick EG, Cattolica EV. Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan. Am J Epidemiol. 1991;134:825–839
  5. Merrill RM, Potosky AL, Feuer EJ. Changing trends in US prostate cancer incidence rates. J Natl Cancer Inst. 1996;88:1683–1685
  6. Xia Z, Roberts RO, Schottenfeld D, Lieber MM, Jacobsen SJ. Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980 to 1994. Urology. 1999;53:1154–1159
  7. Derbes VDP, Leche SM, Hooker CW. The incidence of benign prostatic hypertrophy among the whites and Negroes in New Orleans. J Urol. 1937;38:383–388
  8. Guess HA. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev. 1992;14:131–153
  9. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med. 1995;155:477–481
  10. Jacobsen SJ, Guess HA, Panser L, et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med. 1993;2:729–735
  11. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54:935–944
  12. Platz EA, Kawachi I, Rimm EB, Willett WC, Giovannucci E. Race, ethnicity and benign prostatic hyperplasia in the Health Professionals Follow-up Study. J Urol. 2000;163:490–495
  13. Kaplan SA, Goluboff ET, Olsson CA, Deverka PA, Chmiel JJ. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology. 1995;45:398–405
  14. Martinez M, Maislos S, Rayford W. How to engage the Latino or African American patient with benign prostatic hyperplasia: crossing socioeconomic and cultural barriers. Am J Med. 2008;121:S11–S17[suppl]
  15. Collins MM, Barry MJ, Bin L, Roberts RG, Oesterling JE, Fowler FJ. Diagnosis and treatment of benign prostatic hyperplasia: practice patterns of primary care physicians. J Gen Intern Med. 1997;12:224–229
  16. Monda JM, Oesterling JE. Medical treatment of benign prostatic hyperplasia: 5α-reductase inhibitors and α-adrenergic antagonists. Mayo Clin Proc. 1993;68:670–679
  17. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003) (Chapter 1: diagnosis and treatment recommendations). J Urol. 2003;170:530–547
  18. McConnell JD, Barry MJ, Bruskewitz RC. Benign Prostatic Hyperplasia: Diagnosis and Treatment (Clinical Practice Guidelines Quick Reference Guide for Clinicians). In: Rockville, MD: Agency for Health Care Policy and Research, US Dept of Health and Human Services. February; 1994;p. 1–17AHCPR publication no. 94-0583
  19. Plawker MW, Fleisher JM, Nitti VW, Macchia RJ. Primary care practitioners: an analysis of their perceptions of voiding dysfunction and prostate cancer. J Urol. 1996;155:601–604
  20. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study GroupLepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335:533–539
  21. Medical Therapy of Prostatic Symptoms (MTOPS) Research GroupMcConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–2398
  22. Collins MF, Friedman RH, Ash A, Hall R, Moskowitz MA. Underdetection of clinical benign prostatic hyperplasia in a general medical practice. J Gen Intern Med. 1996;11:513–518
  23. Partin AW. Prostate cancer—educating ourselves and our nonurological colleagues. J Urol. 1996;155:610–611
  24. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53:581–589
  25. Roehrborn CG, Dolte KS, Ross KS, Girman CJ. Incidence and risk reduction of long-term outcomes: a comparison of benign prostatic hyperplasia with several other disease areas. Urology. 2000;56:9–18
  26. Roehrborn CG, Malice M, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology. 2001;58:210–216
  27. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int. 2006;97(suppl 2):3–6discussion 21-22
  28. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. In:  Smedley BD,  Stith AY,  Nelson AR editor. Washington, DC: National Academies Press; 2002;
  29. Lillie-Blanton M, Maddox TM, Rushing O, Mensah GA. Disparities in cardiac care: rising to the challenge of Healthy People 2010. J Am Coll Cardiol. 2004;44:503–508
  30. Collins MM, Meigs JB, Barry MJ, Walker Corkery E, Giovannucci E, Kawachi I. Prevalence and correlates of prostatitis in the Health Professionals Follow-up Study cohort. J Urol. 2002;167:1363–1366
  31. Lepor H. Medical therapy for benign prostatic hyperplasia. Urology. 1993;42:483–501
  32. Lepor H, Williford WO, Barry MJ, Hoakenson C, Jones K Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol. 1998;160:1358–1367
  33. Colon I, Payne R. Benign prostatic hyperplasia and lower urinary tract symptoms in African Americans and Latinos: treatment in the context of common comorbidities. Am J Med. 2008;121(suppl):S18–S26
  34. Haltbakk J, Hanestad BR, Hunskaar S. How important are men's lower urinary tract symptoms (LUTS) and their impact on the quality of life (QOL)?. Qual Life Res. 2005;14:1733–1741
  35. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol. 2003;44:637–649
  36. Wills CE, Holmes-Rovner M, Rovner D, et al. Treatment preference patterns during a videotape decision aid for benign prostatic hyperplasia (BPH). Patient Educ Couns. 2006;61:16–22
  37. Rovner DR, Wills CE, Bonham V, et al. Decision aids for benign prostatic hyperplasia: applicability across race and education. Med Decis Making. 2004;24:359–366
  38. Committee on Communication for Behavior Change in the 21st Century. Improving the Health of Diverse Populations (Speaking of Health: Assessing Health Communication Strategies for Diverse Populations). Washington, DC: The National Academies Press; 2002;
  39. Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol. 2003;44:539–545
  40. Speakman MJ. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what is the available evidence for rational management?. Eur Urol. 2001;39(suppl 3):6–12
  41. Cam K, Akman Y, Kayikci A, Senel F, Erol A. Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms. Int J Urol. 2003;10:582–586
  42. Akduman B, Crawford ED. Terazosin, doxazosin, and prazosin: current clinical experience. Urology. 2001;58(suppl 1):49–54
  43. Kaplan SA, Neutel J. Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology. 2006;67:225–231
  44. Andriole GL, Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44:82–88
  45. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006;97(suppl 2):34–38
  46. Weinrich SP, Boyd MD, Bradford D, Mossa MS, Weinrich M. Recruitment of African Americans into prostate cancer screening. Cancer Pract. 1998;6:23–30
  47. Elder JP, Ayala GX, Campbell NR, Arredondo EM, et al. Long-term effects of a communication intervention for Spanish-dominant Latinas. Am J Prev Med. 2006;31:159–166
  48. Zuvekas A, Nolan L, Tumaylle C, Griffin L. Impact of community health workers on access, use of services, and patient knowledge and behavior. J Ambul Care Manage. 1999;22:33–44
  49. Gary TL, Narayan KM, Gregg EW, Beckles GL, Saaddine JB. Racial/ethnic differences in the healthcare experience (coverage, utilization, and satisfaction) of US adults with diabetes. Ethn Dis. 2003;13:47–54
  50. Perez-Stable EJ, Salazar R. Issues in achieving compliance with antihypertensive treatment in the Latino population. Clin Cornerstone. 2004;6:49–61discussion 62-64
  51. Weissman JS, Betancourt J, Campbell EG, et al. Resident physicians' preparedness to provide cross-cultural care. JAMA. 2005;294:1058–1067

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00510-X

doi: 10.1016/j.amjmed.2008.05.024

The American Journal of Medicine
Volume 121, Issue 8, Supplement 2 , Pages S27-S33 , August 2008

Article Tools